• Publications
  • Influence
Modelling the treated course of schizophrenia: Development of a discrete event simulation model
In schizophrenia, modelling techniques may be needed to estimate the long-term costs and effects of new interventions. However, it seems that a simple direct link between symptoms and costs does notExpand
Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise
ABSTRACT Background: Previous analyses have shown that long-acting risperidone (LAR) is cost-effective in several Western countries. In Portugal, however, the costs of key services are lower.Expand
Modelling approaches: the case of schizophrenia.
Schizophrenia is a chronic disease characterized by periods of relative stability interrupted by acute episodes (or relapses). The course of the disease may vary considerably between patients.Expand
Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.
OBJECTIVES To identify the factors that influence the Scottish Medicines Consortium (SMC) in deciding whether to accept pharmaceutical technologies for use within the Scottish health care system. Expand
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany
Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequencesExpand
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada
Schizophrenia is a chronic, relapsing disease that requires more healthcare resources to manage than any other single psychiatric illness. The main cost of treatment is hospitalization as a result ofExpand
Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events
BackgroundA wide variety of oral antiplatelet trials have been carried out, and a large number of cost-effectiveness estimates based on them have been published. Objective: To assess the costExpand
A Pharmacoeconomic analysis of compliance gains on antipsychotic medications
BackgroundCompliance among patients with schizophrenia is typically poor. Consequently, treatments that are equally efficacious under trial-based conditions but face different compliance rates inExpand
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
BackgroundAs schizophrenia patients are typically suspicious of, or are hostile to changes they may be reluctant to accept generic substitution, possibly affecting compliance. This may counteractExpand
The cost-effectiveness of paliperidone extended release in Spain
Abstract Background: Paliperidone Extended Release OROS (ER) is a new atypical antipsychotic for the treatment of schizophrenia. The objective is, based on a previously published model, to analyzeExpand
...
1
2
3
4
5
...